Jane Street Group, LLC Cellectis S.A. Transaction History

Jane Street Group, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.83 - $3.84 $294,529 - $618,028	-160,945 Reduced 76.11%	50,522 $97,000
Q4 2022 Feb 14, 2023	SELL	$1.85 - $2.6 $244,989 - $344,310	-132,427 Reduced 38.51%	211,467 $444,000
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $335,109 - $597,050	-146,336 Reduced 29.85%	343,894 $819,000
Q2 2022 Aug 16, 2022	SELL	$2.39 - $4.93 $270,124 - $557,203	-113,023 Reduced 18.74%	490,230 $1.36 Million
Q1 2022 May 17, 2022	BUY	$3.45 - $8.77 $1.3 Million - $3.31 Million	376,862 Added 166.47%	603,253 $2.79 Million
Q4 2021 Feb 15, 2022	BUY	$8.01 - $12.84 $449,401 - $720,388	56,105 Added 32.95%	226,391 $1.92 Million
Q3 2021 Nov 16, 2021	BUY	$11.94 - $16.09 $2.03 Million - $2.74 Million	170,286 New	170,286 $2.21 Million
Q1 2021 May 18, 2021	SELL	$18.19 - $33.25 $2.85 Million - $5.21 Million	-156,573 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$15.87 - $31.64 $2.24 Million - $4.46 Million	141,048 Added 908.52%	156,573 $4.67 Million
Q3 2020 Nov 17, 2020	BUY	$15.7 - $20.84 $243,742 - $323,541	15,525 New	15,525 $288,000
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $220,598 - $437,796	-22,672 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$10.15 - $16.89 $230,120 - $382,930	22,672 New	22,672 $233,000
Q3 2018 Nov 14, 2018	SELL	$25.99 - $30.6 $1.14 Million - $1.34 Million	-43,820 Closed	0 $0
Q2 2018 Aug 15, 2018	SELL	$27.78 - $38.53 $127,843 - $177,315	-4,602 Reduced 9.5%	43,820 $1.26 Million
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $1.35 Million - $1.7 Million	48,422 New	48,422 $1.54 Million

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $89.2M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.